

**CURRICULUM VITAE**  
**KATRINE WALLACE, PhD, CPH**  
[kwalla2@uic.edu](mailto:kwalla2@uic.edu)

---

EDUCATION

12/2013      University of Illinois at Chicago      Ph.D.      (Epidemiology)

CREDENTIAL

06/2022      National Board of Public Health Examiners      CPH      (Certified in Public Health)

PROFESSIONAL EMPLOYMENT

University of Illinois at Chicago, School of Public Health, Chicago, IL

01/2022 – present      Adjunct Assistant Professor, Division of Community Health Sciences  
Course:      -Evidence-Informed Community Health Interventions (CHS422)

01/2014 – present      Adjunct Assistant Professor, Division of Epidemiology and Biostatistics  
Courses:      -Intro to Epidemiology (EPI400) – 2 semesters  
                    -Public Health & The Study of Disease & Epidemics (PUBH120)

08/2009 – 12/2013      Teaching Assistant, Division of Epidemiology and Biostatistics  
Courses:      -Intro to Epidemiology (EPI400) – 5 semesters  
                    -Advanced Methods in Epidemiology (EPI501) – 2 semesters

Thomas Jefferson University, College of Population Health, Philadelphia, PA

06-/2022 – present      Lecturer  
Courses:      -Effective Communication and Dissemination of Data (HPA513)  
                    -Descriptive Research Methods (DHS700)  
                    -Statistics I (DHS707)  
                    -Statistics II (DHS708)

RESEARCH GRANTS, FELLOWSHIPS AND HONORS

- US Department of Defense, Congressionally Directed Medical Research Programs (CDMRP), Prostate Cancer Research Program (Grant #W81XW-06-1-0180), \$99,000, 2006-2009
- Midwest Roybal Center Research Pilot Grant, \$5,000, 2008-2010
- National Inst on Aging Predoctoral Research Fellowship, (Grant #T32-AG02050-01A1), 2005-2007
- Paul D. Doolen Graduate Scholarship Award, \$4,000, 2006–Award only given to two students per year
- Delta Omega Honor Society, University of Illinois at Chicago Chapter, 2013

## PROFESSIONAL COMMITTEES

05/2022 – present	Science Communicator, Health Influencer Council, Public Good Projects (PGP)
02/2021 – present	Science Communicator / Vaccine Advocate, Project FIDES, World Health Organization (WHO)
06/2022 – 12/2022	Advisor, Health Information on Social Media, Collaboration between (WHO), Council of Medical Specialty Societies (CMSS), and the National Academy of Medicine (NAM)
05/2021 – 07/2023	Science Communicator / Vaccine Advocate (“Team Halo Guide”) Project Halo, United Nations (UN) Verified Initiative

## RECENT INVITED SPEAKING ENGAGEMENTS

- 1) Invited Panel Member: From Inspiration to Impact: Can Social Media Creators Change the World?, **VidCon 2023**, Baltimore, MD, September 29, 2023
- 2) Invited Panel Member: From Hashtags to Solutions: Leveraging Social Media for Effective Pandemic Preparedness, **Disease Prevention & Control Summit 2023**, Philadelphia, PA, September 7, 2023
- 3) Invited Expert: Nobel Prize Summit on Misinformation "[Truth, Trust & Hope](#)", **National Academy of Sciences**, Washington, DC, May 25, 2023
- 4) Invited Panel Member: Epidemiology & Science Communication During a Pandemic, **Science Talk 2023** Science Communicators Conference, Portland, OR, April 6, 2022
- 5) Invited Speaker: [Strategies for Combatting Health Misinformation](#), **National Library of Medicine 2023 Virtual Symposium on Health Misinformation**, April 5, 2023
- 6) Invited Panel Member: [Building and Sustaining Public Trust in Science](#), **Washington Post Live**, Washington DC, December 6, 2022
- 7) Invited Speaker: [Talking Over the Fence: Going Public with Your Science](#) **University of Illinois Chicago**, Center for Clinical and Translational Science, October 27, 2022.
- 8) Invited Speaker: "[Strategies for Combatting Health Misinformation](#)", **Hiram College**, October 19, 2022.
- 9) Invited Speaker: "[Strategies for Combatting Health Misinformation](#)", **University of Alabama at Birmingham**, October 15, 2022.
- 10) Invited Panel Member: [Best Practices for Establishing an Effective Online Presence: a Panel Discussion for Academics](#), SoCal Clinical and Translational Science Institute, June 1, 2022
- 11) Invited Speaker: "[The Health Risks of Misinformation](#)", University of Illinois at Chicago Alumni Exchange, May 19, 2022.
- 12) Invited Speaker: "[Misinformation as a Risk Factor Exacerbating the COVID-19 Pandemic](#)", University of Alabama at Birmingham, April 26, 2022.
- 13) Invited Panel Member: Combatting Mis/Dis-information with Science Communication, NIH Clinical and Translational Science Awards Program, McCormick Place, Chicago, April 23, 2022
- 14) Invited Panel Member: "[The Medical Beat: Battling Mis/Dis-Information During Health Care Communications](#)", Knight Media Forum, February 24, 2022
- 15) Invited Speaker: "COVID-19 vaccines and why you should believe the science" (speaking to employees at Mission Cloud Services corporation), September 16, 2021
- 16) Invited Speaker: 'Communicating Scientific Information to the Public' Great Lakes Pharmacovigilance and Drug Safety Forum, University of Illinois at Chicago, October 1, 2021
- 17) Invited Spotlight Session Panel Member: "[Social Media for Advocacy](#)" Meeting of the American Public Health Association (APHA) October 2021
- 18) Invited Panel Member: "The Importance of Social Media in Public Health Messaging; Adapting to this Generation's Methods of Communication", Meeting of the American Public Health Association (APHA) October 2021
- 19) Invited Speaker: "Vaccines and the Delta Variant" – Immunize Nevada, NILE expert speaker (Nevada Immunization Learning and Education) October 13, 2021)
- 20) Invited Panel Member: "[When Misinformation Goes Viral: Using TikTok to Fight Disinformation](#)" – October 20, 2021 Panel Discussion with New York University GPH and NYU Steinhart

- 21) Invited Panel Member: “Debunking vaccine misinformation” (speaking to vaccine-hesitant employees at TIAA corporation), November 16, 2021
- 22) Invited Speaker: ‘Communicating Vaccine Information to the Public’, University of Illinois at Chicago, School of Pharmacy, December 2, 2021
- 23) Invited Panel Member: “[The co-epidemic of COVID-19 and misinformation](#)”, November 19, 2021

## SCIENTIFIC JOURNAL PUBLICATIONS

1. Peipert JD, Goble S, Isaacson J, Tang X, **Wallace K**, Coleman RL, Ledermann JA, Cella D. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial. *Gynecol Oncol.* **2023** May 30;175:1-7.
2. **Wallace KL** and Malaty-Rivera J “Why Aren’t We Better Protecting our Youngest Children Against Infection?”. *ContagionLive*, V.7, No 6, **Dec 2022**.
3. Reid R, Xie Y, Shi J, **Wallace KL** Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer, *J Clin Pathways.* **2022**;8(4):38-46.
4. Malaty-Rivera J and Wallace KL, “Considering Mandatory Covid-19 Vaccines for Schools”. *ContagionLive*, V.7, No 2, May 2022.
5. Reid R, Xie Y, Shi J, Wallace KL Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer, *J Clin Pathways.* 2022;8(4):38-46.
6. Wallace KL, “Vaccines work: Misreading the Data May Make You Think Otherwise” *The Hill*, August 27, 2021. <https://thehill.com/opinion/healthcare/569730-covid-19-vaccines-work-misreading-the-data-can-make-you-think-otherwise/>
7. Wallace, KL, Landsteiner A, Bunner S, Engel-Nitz, N, Luckenbaugh A. Increasing Prevalence of Metastatic Castration-Resistant Prostate Cancer in a Managed Care Population in the United States. *Cancer Causes and Control*, 2021 Dec;32(12):1365-1374
8. Wallace, KL., Adamski, K., Pai, A., Chawla A. The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer. *Pharmacoeconomics* 2021 Feb;39(2):231-241.
9. Wallace, KL, Goble, S., Isaacson, J. et al. Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”. *Pharmacoeconomics* 2019 Aug;37(8):1065-1067
10. Furner SE, Wallace KL, Arguelles L, Miles T, Goldberg J. Factors associated with self-reported health: a twin study of older African American women. *J Women Aging.* 2010;22(2):83-93.
11. Wallace, KL, Furner SE, Freeman, VF and Davis FM. Racial trends in prostate cancer incidence rates for Illinois & the United States;1986-2000. *Journal of Registry Mgmt.* 33:4,108-110 (2006).
12. Furner SE, Wallace KL, Arguelles LM, Miles T, Goldberg J, Twin Study of Depressive Symptoms Among Older African-American Women, *The Journals of Gerontology: Series B*, Volume 61, Issue 6, November 2006, 355–P361.
13. Latini, D.M., Penson, D.F., Wallace, KL, Lubeck, D.L., Lue, T.F., Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. *J Sex Med.* 2006 Nov;3(6):1068-7
14. Latini, D.M., Penson, D.F., Wallace, KL, Lubeck, D.L., Lue, T.F., Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. *J Sex Med.* 2006 Nov;3(6):1059-67.
15. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace KL, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR, Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE, *Journal of Urology.* 2005 Mar;173(3):732-6
16. Wallace, KL, Riedel, A, Joseph-Ridge, N, and Wortmann, R. Increasing Prevalence of Gout and Hyperuricemia Among Older Adults in a Managed Care Population. *Journal of Rheumatology*, 2004 August
17. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, Carroll, PR. Watchful Waiting and Health-Related Quality of Life for Patients with Localized Prostate Cancer: Data from CaPSURE. *Journal of Urology.* 2004 Nov;172(5, Part 1 of 2):1830-1834.

18. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. Patterns of Practice in the United States: Insights from CaPSURE on Prostate Cancer Management. *Current Urology Reports*. 2004 Jun;5(3):166-72.
19. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll PR. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a communitybased cohort: results from cancer of the prostate strategic urological research endeavor (capsure). *The Journal of Urology*. 2004 Jun;171(6 Pt 1):2255-9.
20. Riedel, A, Nelson, M, Joseph-Ridge, N, Wallace, KL, MacDonald, P and Michael Becker, Compliance with Allopurinol Among Managed Care Enrollees with Gout. *Journal of Rheumatology* 2004, August
21. Riedel, A, Nelson, M, Wallace, KL, Joseph-Ridge, N, Cleary, M and Adel Fam. Prevalence of Comorbid Conditions and Prescription Medication Use Among Older Patients with Gout in a Managed Care Setting. *Journal of Clinical Rheumatology* 2004, December
22. Penson, D.F., Latini, D.M., Wallace, KL, Henning, J.M., Lue, T.F., Lubeck, D.L. Is the impact of erectile dysfunction on quality of life different in men with prostate cancer than in men with erectile dysfunction due to other causes?: Results from the ExCEED database. *The Journal of Urology*. 2003 Apr;169(4):1458-61
23. Latini, D.M., Penson, D.F., Lubeck, D.L., Wallace, KL, Henning, J.M., Lue, T.F. Longitudinal Differences In Disease-Specific Quality Of Life For Men With Erectile Dysfunction *The Journal of Urology*. 2003 Apr;169(4):1437-1442.
24. Penson, D.F., Latini, D.M., Lubeck, D.L., Wallace, KL., Henning, J.M., Lue, T.F., Diabetic men with erectile dysfunction are unique from the general population of impotent men. *Diabetes Care*. 2003 Apr;26 (4):1093-1099.

#### SCIENTIFIC CONFERENCE PRESENTATIONS

1. RL Reid, Y Xie, J Shi, KL Wallace Real-world progression-free (PFS) and overall survival (OS) for utilizing second-line PARPi maintenance therapy vs active surveillance for. ASCO June 2022
2. Barber E, Saiz A, Bunner S, Engel-Nitz N, Wallace, KL. Duration of treatment, treatment adherence and treatment discontinuations associated with second-line PARP inhibitor or bevacizumab maintenance regimens for recurrent ovarian cancer. SGO Annual Meeting on Women's Cancer, March 2022.
3. Saiz A, Wallace, KL, Bunner S, Engel-Nitz N, Barber E. Duration of treatment, treatment adherence and treatment discontinuations associated with second-line PARP inhibitor or bevacizumab maintenance regimens for recurrent ovarian cancer. Winter SGO, December 2021.
4. Reid R, Shi J, Monette, A, Wallace KL Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer. Presented at ASCO 2021
5. Reid R, Xie Y, Shi J, Wallace KL Real-world data analysis of the utilization of second-line PARPi therapy for patients with advanced ovarian cancer. Presented at IGCS 2021
6. Reid R, Xie Y, Shi J, Wallace KL Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer. Presented at ASCO 2021
7. Moses KA, Wallace KL, Landsteiner A, Bunner S, Engel-Nitz N, Lal LS, Golsorkhi, AA. Real-world evidence of Clinically Significant Events (CSEs) Associated with Treatment of metastatic castrationresistant prostate cancer (mCRPC) in a managed care population in the United States. Presented at ASCO GU, February 2021
8. Wallace KL, Adamski KA, Rose D, Chawla A. The Budget Impact of Adding Rucaparib to a Managed Care Formulary for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Accepted for presentation at AMCP Nexus October 2020.
9. Moses KA, Wallace KL, Landsteiner A, Bunner S, Engel-Nitz N, Lal LS, Golsorkhi, AA. Real-world evidence of treatment patterns and pharmacy costs among patients with metastatic castrationresistant prostate cancer (mCRPC) in a managed care population in the United States. *Journal of Clinical Oncology*, Volume 38, Issue 15\_suppl e19319. 2020
10. Wallace KL, Landsteiner A, Bunner S, Engel-Nitz N, Lal LS, Golsorkhi, AA., Luckenbaugh A. Epidemiology and Mortality of Metastatic Castration-Resistant Prostate Cancer (mCRPC) in a

Managed Care Population in the United States, Journal of Clinical Oncology, Volume 38, Issue 15\_suppl e19319. 2020

11. Dippel E, Parikh N, Wallace K. Use of Spider FX Embolic Protection Device vs Distal Embolic Event; Health Economic Study of Inpatient and Outpatient Settings of Care; Presented at International Society of Endovascular Therapy (ISET), Hollywood, FL., February, 2015.
12. Dippel E, Parikh N, Wallace K. Use of Spider FX Embolic Protection Device vs Distal Embolic Event; a Health Economic Analysis. Presented at Transcatheter Therapeutics (TCT)., October, 2014.
13. Jaff M, Wallace K, Zeller. Economic Analysis of the Stellarex™ Drug-Coated Balloon Compared to Uncoated Balloons for Treatment of Femoropopliteal Peripheral Artery Disease. Presented at Transcatheter Therapeutics (TCT)., October, 2014.
14. Niazi K., Grabner M., Wallace K. Long-term Cost Patterns of Directional Atherectomy vs. Other Treatment Choices for Diabetes Patients with Peripheral Artery Disease: a 24-Month Analysis of Administrative Claims Data. Presented at Transcatheter Therapeutics (TCT)., October, 2014.
15. Niazi K., Grabner M., Wallace K. Long-term Cost Patterns of Directional Atherectomy vs. Other Treatment Choices for Patients with Peripheral Artery Disease: a 24-Month Analysis of Administrative Claims Data. Presented at New Cardiovascular Horizons (NCVH)., May, 2014.
16. Dippel E, Parikh N, Egeland R, Wallace K. Distal embolization and protective devices: mortality, operating room time, length of stay and costs. Presented at Transcatheter Therapeutics (TCT)., October, 2013.
17. Niazi K., Grabner M., Wallace K. Long-term Cost Patterns of Directional Atherectomy vs. Other Treatment Choices for Diabetes Patients with Peripheral Artery Disease: a 12-Month Analysis of Administrative Claims Data. Presented at Transcatheter Therapeutics (TCT)., October, 2013.
18. Niazi K., Grabner M., Wallace K. Long-term Cost Patterns of Directional Atherectomy vs. Other Treatment Choices for Patients with Peripheral Artery Disease: a 12-Month Analysis of Administrative Claims Data. Presented at New Cardiovascular Horizons (NCVH)., May, 2013.
19. Wallace K, Hashemi L, Minshall M. Costs, length of stay and all-cause mortality in ruptured versus unruptured cerebral aneurysm among inpatients in the United States. Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Latin American Congress 2011 in Mexico City, MX 6/4/2011
20. Wallace KL, Hashemi L, Minshall M, Niazi K. Costs and Length of Stay for Atherectomy Procedures in a United States Managed Care Population. New Cardiovascular Horizons (NCVH) 2011 Annual Meeting in New Orleans, LA, 6/4/2011
21. Wallace KL, Minor S, Krantz A. Prevalence of heroin use and Heroin-related asthma symptoms in an inner-city asthmatic population. Podium presentation at the American Public Health Association (APHA) 2007 Annual Meeting in Washington, DC, 11/5/2007
22. Wallace, KL, Furner SE, Freeman, VF and Davis FM. Racial trends in prostate cancer incidence rates for Illinois and the United States; 1986-2000. Poster presented at the American Public Health Association (APHA) 2006 Annual Meeting in Boston, MA 11/8/2006.
23. Furner SE, Wallace KL, Arguelles LM, Miles T, Goldberg J, A Twin Study of Factors Associated with Self -Reported Health among Older African American Women. Presented at the Gerontological Society of America (GSA) Annual Meeting 2006, Dallas, TX 11/18/2006
24. Pearce D, Wallace KL, Kulkarni A, Balkrishnan R, Feldman S, Psoriasis and work productivity, American Academy of Dermatology 2005 Annual Meeting. New Orleans, LA. February 2005
25. Wallace KL, Chen D, Heffernan M, Langley R, Menter A. Quality of life in moderate to severe plaque psoriasis patients receiving 24 weeks of adalimumab therapy. JEADV 2005; 18 (Suppl 2) 359.
26. Wallace, KL, Hamlin R, Langley R, Chen D, et al. Results of the DLQI Dermatology-Specific Quality of Life Measure in Moderate to Severe Plaque Psoriasis Patients Receiving 12 Weeks of Adalimumab Therapy, Presented at the summer meeting of the American Academy of Dermatology (AAD), New York, NY. July, 2005.
27. Wallace, KL, Miller, B, Heffernan M, Chen D. Results of the SF-36 General Health Status Measure in Moderate to Severe Chronic Plaque Psoriasis Patients Treated with Adalimumab for 12 Weeks. Presented at the summer meeting of the American Academy of Dermatology (AAD), New York, NY. July, 2005.
28. Wallace, KL, Elkin, E.P, Latini, D.M., Carroll, P.M. Timing of LHRH treatment after PSA failure in prostate cancer patients: A Survival Analysis from the CaPSURE database. Abstract accepted for discussed poster session at American Urological Association (AUA) Annual Meeting 2004.

29. Wallace, KL, Riedel, A, Joseph-Ridge, N, and Wortmann, R. , Increasing Prevalence of Gout and Hyperuricemia Among Older Adults in a Managed Care Population. Accepted for poster presentation at the National Medical Association (NMA) Annual meeting, 2004
30. Riedel, A, Nelson, M, Wallace, KL, Joseph-Ridge, N, Cleary, M and Adel Fam. Prevalence of Comorbid Conditions and Prescription Medication Use Among Older Patients with Gout in a Managed Care Setting. Accepted for poster presentation at the National Medical Association (NMA) Annual meeting, 2004
31. Kane, C.J., Bassett, W.W., Sadetsky, N., Silva, S., Wallace, K.L., Pasta, D.J., Cooperberg, M.R., Chan, J, Carroll, P.R., Is obesity associated with more aggressive prostate cancer? (Data from CaPSURE). Abstract accepted for poster presentation at American Urological Association (AUA) Annual Meeting 2004.
32. Arredondo, SA., Elkin, E.P., Marr, P.L., Latini, D.M., Wallace, K.L., Carroll, P.R. Comorbidity and Health Related Quality of Life in Men with Prostate Cancer: Data from CaPSURE. Abstract accepted for poster presentation at American Urological Association (AUA) Annual Meeting 2004.
33. Chan, J.M., Elkin, E.P., Silva, S., Wallace, K.L., Broering, J., Carroll, P.R., Contemporary Complementary and Alternative Medicine Use among Men with Prostate Cancer-Data from CaPSURE. Abstract accepted for poster presentation at American Urological Association (AUA) Annual Meeting 2004.
34. Latini, DM, Elkin, EP, Cooperberg, MR, Sadetsky, N., Wallace, KL, Carroll, PR., Differences in Clinical Characteristics And Disease-Free Survival For Latino, African-American, And Non-Latino White Men with Prostate Cancer: Data From CaPSURE?. Abstract accepted for poster presentation at American Urological Association (AUA) Annual Meeting 2004.
35. Meng, MV, Elkin, EP, Latini, DM, Wallace, KL, Carroll, PR., Management of Patients With High-Risk Localized Prostate Cancer: Data From CaPSURE. Abstract accepted for poster presentation at American Urological Association (AUA) Annual Meeting 2004.
36. Purohit, R, Silva, S, Lubeck, DP, Wallace, KL, Carroll, PR, Predictors of Adverse Health-related Quality of Life Outcomes in Men, Undergoing Androgen Deprivation Therapy. Abstract accepted for poster presentation at American Urological Association (AUA) Annual Meeting 2004.
37. Wallace, KL, Riedel, A, Nelson, M, Joseph-Ridge, N., MacDonald, P and Michael Becker, Compliance with Allopurinol Among Managed Care Enrollees with Gout. Abstract accepted for poster presentation at: American College of Rheumatology (ACR), 2003.
38. Wallace, K.L., Latini, D.M., Penson, D.F., Henning, J.M., Lubeck, D.L., Lue, T.F. Longitudinal differences in psychological adjustment for men with erectile dysfunction: results from ExCEED.- Abstract accepted for poster presentation at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2003
39. Wallace, K.L., Latini, D.M., Penson, D.F., Henning, J.M., Lubeck, D.L., Lue, T.F. Predictors of response to erectile dysfunction treatment at 12 months: results from the ExCEED database.- Abstract accepted for poster presentation at: : International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2003.